Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
New research suggests amyloid β and BACE1 may protect the brain by binding toxic metals, rather than causing Alzheimer’s.
-
Dublin, March 03, 2025 (GLOBE NEWSWIRE) -- The "Neurology Market: Research Overview" report has been added to ResearchAndMarkets.com's offering.The Neurology Market was valued at USD 67.3 Billion...
-
Longeveron to present at investor conference - Planet MicroCap Showcase - May 1, 2024.
-
Longeveron prices $5.15 million public offering with certain board member and insider participation.
-
Dublin, June 05, 2023 (GLOBE NEWSWIRE) -- The "Immunoassay for Neurological Biomarkers Market Size, Share & Trends Analysis Report By Product, By Disease (Alzheimer's Disease, Parkinson's...
-
MIAMI, April 05, 2023 (GLOBE NEWSWIRE) -- ADvantage Therapeutics, Inc. (“ADvantage” or “the Company”), which is developing therapies to treat neurodegenerative conditions with a central focus on...
-
New York, United States, Oct. 24, 2022 (GLOBE NEWSWIRE) -- According to a research report published by Spherical Insights & Consulting, the Global Alzheimers Disease Diagnostics and Therapeutics...
-
REHOVOT, Israel, Feb. 25, 2020 (GLOBE NEWSWIRE) -- Todos Medical Ltd. (OTCQB: TOMDF), a clinical-stage in-vitro-diagnostics company focused on the development of blood tests for the early detection...
-
Topline results expected before the end of Q1/2020 REHOVOT, Israel and NEW YORK, Nov. 14, 2019 (GLOBE NEWSWIRE) -- Todos Medical Ltd. (OTCQB: TOMDF), a clinical-stage in-vitro diagnostics company...
-
REHOVOT, Israel and SINGAPORE, Sept. 13, 2019 (GLOBE NEWSWIRE) -- Todos Medical Ltd. (OTCQB: TOMDF), a clinical-stage in-vitro diagnostics company focused on the development of blood tests for the...